Welcome to the 20th edition of OBN’s flagship two-day conference, BioTrinity 2026, designed to catalyse growth for all who attend. This immersive event attracts an international audience of approximately 850 delegates, encompassing academic entrepreneurs, emerging R&D companies, funders and investors, Big Pharma teams, regulatory bodies, and professional supporters.

The 2026 agenda is enhanced by a showcase of 100 research updates (ranging from Academic Posters to Series B companies), a dedicated one-day session exploring international market growth, and a new, much-demanded ‘mentor match-making lunch’ for early-stage Founders and CEOs.

Attendees will also benefit from an increased Big Pharma presence and focused efforts on unlocking access to alternative sources of funding.